AtaiBeckley Inc. (NASDAQ: ATAI) related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, AtaiBeckley shareholders are expected to receive $6.75 per share in cash, plus up to $2.50 per share in the form of a Contingent Value Right entitling the holder to additional cash payments upon achievement of specified development and regulatory milestones related to the BPL-003 and VLS-01 programs.